Announcement of Lianhuan Pharmaceutical on the signing of the "Pharmaceutical Precision Cold Chain Manufacturing Center Project Admission Contract" with Yangzhou High-tech Industrial Development Zone
Securities code: 600513 Securities abbreviation: Lianhuan Pharmaceutical Announcement number: 2026-027
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Regarding the signing between the holding subsidiary and Yangzhou High-tech Industrial Development Zone
Announcement of "Pharmaceutical Precision Cold Chain Manufacturing Center Project Admission Contract"
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Investment project name: Lianhuan Marketing Pharmaceutical Precision Cold Chain Manufacturing Center Project
Total investment amount: RMB 300 million
This investment has been reviewed and approved at the 23rd extraordinary meeting of the company's ninth board of directors. This investment does not constitute a major asset restructuring stipulated in the "Administrative Measures for Major Asset Reorganization of Listed Companies", nor does it constitute a related transaction, and does not need to be submitted to the shareholders' meeting for review.
The core contents such as the overall investment scale and implementation period listed in the contract for entering the park are all planned numbers and forward-looking estimates at the current stage. There are uncertainties. Subsequent adjustments and optimization may be made based on factors such as the policy environment, market changes, and actual operations.
There are certain uncertainties in the land use, land layout, development and utilization methods, planning function positioning and other matters within the project planning scope in this park entry contract. They will be dynamically adjusted based on policy requirements, approval results and actual development needs. The official approval and actual implementation plan will prevail.
This investment still needs to be approved by the state-owned assets authority, so there is uncertainty. Investors are kindly requested to invest rationally and pay attention to investment risks.
1. Overview of foreign investment
(1) Overview of this transaction
- Overview of this transaction
In order to ensure the long-term development of Yangzhou Lianhuan Pharmaceutical Marketing Co., Ltd. (full text referred to as "Lianhuan Marketing"), a subsidiary of Jiangsu Lianhuan Pharmaceutical Co., Ltd. (full text referred to as "Lianhuan Pharmaceutical", the "Company"), with the advancement of product optimization, market expansion and intelligent construction, in order to ensure the efficient operation of Lianhuan Marketing's core businesses such as warehousing, logistics and office, and improve management standardization and logistics efficiency, Lianhuan Marketing plans to sign the "Pharmaceutical Precision Cold Chain Manufacturing Center Project Admission Contract" with Yangzhou High-tech Industrial Development Zone and apply for new operating land. The land applied for this time is mainly used to build a standardized pharmaceutical storage center, modern logistics operation area and related supporting office facilities. The total planned investment amount of the project is RMB 300 million, of which the fixed asset investment is not less than RMB 165 million.
- Transaction elements of this transaction
□Newly established company
□Increase capital in existing companies (□Same proportion □Not the same proportion)
--Type of company before capital increase: □ Wholly owned subsidiary □ Holding subsidiary □ Participating investment type
Company with shares □ Company with no shares held
Invest in new projects
□Others: _________
Name of investment target Lianhuan Marketing Pharmaceutical Seiko Cold Chain Manufacturing Center Project
Determined, specific amount (10,000 yuan) 30,000.00
Investment amount Not yet determined
Cash
□Own funds
□Raise funds
Bank loan
Investment method
□Others:_____
□Physical assets or intangible assets
□Equity
□Others:______
Is it cross-border □Yes No
(2) The company held the 23rd extraordinary meeting of the ninth board of directors on April 27, 2026, and reviewed and approved the "Proposal on the Company's Controlled Subsidiary to Sign the "Pharmaceutical Precision Cold Chain Manufacturing Center Project Admission Contract" with the Yangzhou High-tech Industrial Development Zone. According to the "Shanghai Stock Exchange Stock Listing Rules" and the "Articles of Association" and other relevant regulations, this investment does not need to be submitted to the company's shareholders' meeting for review.
(3) This investment does not constitute a related transaction, nor does it constitute a major asset reorganization as stipulated in the "Administrative Measures for Major Asset Reorganization of Listed Companies".
2. Basic information on investment targets
(1) Basic situation of the project
Investment Type Investment in new projects
Project name Yangzhou Lianhuan Pharmaceutical Marketing Co., Ltd. Pharmaceutical Precision Cold Chain Manufacturing Center Project The project application land is about 40 acres, with a planned total construction area of about 10,000 square meters. The main construction complies with the new version of GSP standards and the main content of the "Pharmaceutical Modern Logistics Standardization Construction Guide" project
Standardized drug storage center, modern logistics operation area and supporting office facilities required by the Guiding Opinions.
Construction location: South Park of Yangzhou High-tech Industrial Development Zone (National High-tech Zone)
Total investment amount of the project (10,000 yuan) 300,000,000 yuan
Whether it belongs to the main business scope Yes □No
(2) Capital contributions of major investors
Lianhuan Marketing invested RMB 300 million, and the source of funds was Lianhuan Marketing's self-raised funds.
(3) Current progress of the project
The project is currently in the preliminary preparation stage.
3. Main contents of foreign investment contracts
The main contents of the "Pharmaceutical Precision Cold Chain Manufacturing Center Project Admission Contract" to be signed between Lianhuan Marketing and the Yangzhou High-tech Industrial Development Zone Management Committee are as follows:
Party A: Yangzhou High-tech Industrial Development Zone Management Committee
Party B: Yangzhou Lianhuan Pharmaceutical Marketing Co., Ltd.
In accordance with the "Civil Code of the People's Republic of China", the "Land Management Law of the People's Republic of China" and other laws and regulations as well as relevant regulations of the country, Jiangsu Province and Yangzhou City, after friendly negotiation between the two parties, the following agreed terms have been reached on Party B's proposed investment in the pharmaceutical precision cold chain manufacturing center project within the jurisdiction of Party A:
Investment scale: Party B uses 40 acres of land within Party A's jurisdiction to invest in the construction of a pharmaceutical precision cold chain manufacturing center project. The total planned investment in the project is RMB 300 million, of which the fixed asset investment is not less than RMB 165 million.
Project location and land area: The project site is located in the South Park of Yangzhou High-tech Industrial Development Zone. The specific location is east of Jianjiang 1st Road of Bio-Health Industrial Park, south of Lianhuan Yihetang project, west of Yangli Expressway and north of Heng 2nd Road. The planned land area is approximately 40 acres (the specific area and four boundaries shall be determined by the natural resources and planning departments).
Nature of project land use and transfer period: The nature of the above-mentioned land is industrial, and the transfer period of land use rights is 30 years. Party B shall not change the nature of the land use without the approval of Party A and relevant government departments for project land use.
Land listing price: Party A agrees to supply project land to Party B at the lowest provincial controlled price in the region. The starting land transfer listing price is 210,000 yuan/mu (excluding transaction service fees, deed taxes and other taxes).
Acquisition of land use rights: Transfer by public listing. Party B shall pay a deposit and participate in the bidding in accordance with the listing announcement requirements and procedures of the natural resources and planning management department at that time, and delist the land in accordance with laws and regulations. After the delisting is completed, Party B is responsible for signing the land transfer contract and ancillary agreements (industrial land project supervision agreement and performance bond agreement), and performing them as agreed.
Liability for land breach of contract: (1) After Party B obtains the land use rights, it shall carry out project construction on schedule in accordance with the requirements of relevant national and local regulations and the approved plan as well as the agreement between Party A and Party B. If Party B cannot start construction on schedule, it must apply to Party A in advance and the matter shall be resolved through negotiation between the two parties. If Party B fails to develop, construct and utilize the land in accordance with the regulations or agreed content, Party A has the right to work with relevant departments to dispose of the land in accordance with the agreed content and relevant regulations. If Party B fails to enter the site and start construction within 3 months after receiving the "Construction Permit", or starts construction but continues to stop it for more than 6 months, Party A has the right to take corresponding measures in conjunction with relevant departments, cancel Party B's land use right certificate, and recover the land use rights with or without compensation in accordance with laws and regulations.
(2) If Party A is unable to deliver the land parcel to Party B within the stipulated time due to reasons, Party A will pay a liquidated damages of 0.1% of the total purchase and sale price for each overdue day. If the overdue date exceeds 60 days, the contract can be terminated, the full price refunded and liquidated damages paid. If Party B is unable to obtain the land transfer certificate for the land parcel due to national policy adjustments or force majeure in nature, Party A is responsible for coordinating the relevant departments and returning to Party B the land transfer money it has collected in full (the land transfer fee does not bear interest).
(3) If Party B is legally revoked of its business license, ordered to close down, disbanded, or other abnormal production and operation situations, or fails to produce and operate normally for three years from the start of construction, or directly or indirectly transfers the project land, Party A or the relevant competent authorities have the right to take back the land use rights and the buildings and attachments on the ground. However, before taking back, Party B should be notified in writing and explain the reasons, and Party B should be given a 90-day appeal period. After the resumption, appropriate compensation will be paid with reference to the government demolition appraisal price or market appraisal price, whichever is higher (the above-mentioned methods can be used to pay compensation for above-ground buildings and attachments, and the land transfer fee is recommended to be converted according to the service life).
Key points for intensive land use: project construction floor area ratio, building density, and building setback road distance shall be subject to the planning and design key points of the natural resources and planning department.
Liability for breach of contract: If Party A fails to perform the relevant provisions of this Agreement as scheduled, Party B has the right to require Party A to compensate for the actual losses caused to Party B. If Party A fails to perform its obligations under this contract and thereby affects Party B's project construction and target company operations, Party B will not be liable for breach of contract under this agreement.
4. Impact of foreign investment on the company and its subsidiaries
This investment is mainly used by the subsidiary to build a modern pharmaceutical warehousing and logistics center and comprehensive operation base to improve the standardization level of the subsidiary's warehousing management and logistics distribution efficiency, which will help support the subsidiary's future business expansion needs, is in line with the long-term strategic planning of the company and its subsidiaries, and will not harm the interests of the company, its subsidiaries or small and medium-sized investors.
This project investment is an investment for the long-term development of the company and its subsidiaries, and will not have a significant impact on the financial status and performance of the company and its subsidiaries in the short term.
5. Risk warning of foreign investment
(1) The core contents such as the overall investment scale and implementation period listed in the contract for entering the park are all planned numbers and forward-looking estimates at the current stage. There are uncertainties. Subsequent adjustments and optimization may be made based on factors such as the policy environment, market changes, and actual operations.
(2) There are certain uncertainties in the land use, land layout, development and utilization methods, planning function positioning and other matters within the project planning scope in this park entry contract. They will be dynamically adjusted based on policy requirements, approval results and actual development needs. The final official approval and actual implementation plan shall prevail.
(3) This investment still needs to be approved by the competent state-owned assets department, so there is uncertainty. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jiangsu Lianhuan Pharmaceutical Co., Ltd.
April 28, 2026